Page last updated: 2024-11-04

sulforaphane and Smoking Cessation

sulforaphane has been researched along with Smoking Cessation in 1 studies

sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.

Smoking Cessation: Discontinuing the habit of SMOKING.

Research Excerpts

Excerpt	Relevance	Reference
"Patients with chronic obstructive pulmonary disease (COPD) have high oxidative stress associated with the severity of the disease."	2.90	Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. ( Berenson, CS; Biswal, S; Burke, A; Criner, GJ; Fahey, JW; Holbrook, JT; Jacobs, MR; Sethi, S; Sidhaye, VK; Sudini, KR; Thimmulappa, R; Wise, RA, 2019)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Sidhaye, VK	1
Holbrook, JT	1
Burke, A	1
Sudini, KR	1
Sethi, S	1
Criner, GJ	1
Fahey, JW	1
Berenson, CS	1
Jacobs, MR	1
Thimmulappa, R	1
Wise, RA	1
Biswal, S	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Enhancing Nrf2 by Sulforaphane Treatment in COPD[NCT01335971]			Phase 2	89 participants (Actual)	Interventional	2010-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C1 at 4 Weeks

The fifth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C1 (AKR1C1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
Placebo	1.45
Sulforaphane 25	1.08
Sulforaphane 150	0.79

Change From Baseline in Bronchial Epithelial Cell Expression of AKR1C3 at 4 Weeks

The sixth primary design variable is the change from baseline in expression of Aldo-Keto Reductase Family 1 Member C3 (AKR1C3) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
Placebo	1.10
Sulforaphane 25	1.38
Sulforaphane 150	0.87

Change From Baseline in Bronchial Epithelial Cell Expression of HO1 at 4 Weeks

The fourth primary design variable is the change from baseline in expression of Heme Oxygenase 1 (HO1) in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
Placebo	1.05
Sulforaphane 25	1.12
Sulforaphane 150	0.93

Change From Baseline in Bronchial Epithelial Cell Expression of Nrf2 at 4 Weeks

The second primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in bronchial epithelial cells (BEC) at 4 weeks by analysing Nrf2 protein. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
Placebo	1.09
Sulforaphane 25	1.06
Sulforaphane 150	1.06

Fold-change in Isoprostane Concentrations (Follow-up to Baseline)

Isoprostane, an oxidant stress indicator, was measured in expired breath condensate at baseline and 4 weeks. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
Placebo	1.18
Sulforaphane 25	0.83
Sulforaphane 150	0.64

Change From Baseline in Alveolar Macrophage Expression of Nrf2 and Associated Genes at 4 Weeks

The first primary design variable is the change from baseline in nuclear factor erythroid 2 like 2 (Nrf2) expression in alveolar macrophages (AM) at 4 weeks by analysing Nrf2 protein and expression of a panel of Nrf2 regulated genes.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
	NQ01	HO1	AKR1C1	AKR1C3	Nrf2	Keap1
Placebo	0.80	0.90	0.81	1.03	1.14	0.94
Sulforaphane 150	0.94	1.06	0.71	0.87	1.13	1.06
Sulforaphane 25	1.03	0.98	1.13	1.02	1.05	0.99

Change From Baseline in Bronchial Epithelial Cell Expression of NQ01 and Keap1 at 4 Weeks

The third primary design variable is the change from baseline in NAD(P)H Quinone Dehydrogenase 1 (NQ01) and Kelch Like ECH Associated Protein 1 (Keap1) expression in bronchial epithelial cells (BEC) at 4 weeks. Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage for primary outcome data. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
	NQ01	KEAP1
Placebo	1.09	1.12
Sulforaphane 150	0.96	0.87
Sulforaphane 25	1.12	1.39

Fold-change in Inflammatory Marker Concentrations in Bronchial Alveolar Lavage (Follow-up to Baseline) by Treatment Group

Inflammatory markers were measured in bronchial alveolar lavage samples at baseline and 4 weeks in the participants of this trial who had bronchoalveolar lavage samples obtained.Three participants - one from each treatment group - were unable to complete follow-up bronchoalveolar lavage. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
	Interleukin-8 (pg/mg)	Secretory leukoprotease inhibitor (pg/mg)
Placebo	1.22	1.51
Sulforaphane 150	1.11	1.12
Sulforaphane 25	0.94	1.09

Fold-change in Plasma Inflammatory Marker Concentrations (Follow-up to Baseline)

Inflammatory markers were measured in plasma at baseline and 4 weeks. Thiobarbituric acid reactive substances were measured in nmol malondialdehyde (MDA)/mL. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
	Isoprostane (ng/mg)	Thiobarbituric acid reactive substances	Total antioxidants (mM Trolox equivalents/L)
Placebo	0.89	0.96	0.97
Sulforaphane 150	0.88	1.06	0.97
Sulforaphane 25	0.90	1.05	0.92

Fold-change in Serum Inflammatory Marker Concentrations (Follow-up to Baseline)

Inflammatory markers were measured in serum samples derived from venipuncture at baseline and 4 weeks in the serum of the participants of the trial. (NCT01335971)
Timeframe: Baseline and 4 weeks

Intervention	fold change (Median)
	C-reactive protein (mg/L)	Interleukin-6 (pg/mL)	Interleukin-8 (pg/mL)
Placebo	0.99	0.75	1.06
Sulforaphane 150	1.01	1.12	1.03
Sulforaphane 25	0.90	0.90	1.04

Trials

1 trial available for sulforaphane and Smoking Cessation

Article	Year
Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. Respiratory research, 2019, Aug-20, Volume: 20, Issue:1 Topics: Aged; Antioxidants; Bronchi; Double-Blind Method; Epithelium; Female; Gene Expression; Humans; Infla	2019